AR062012A1 - Pirazoles como activadores de glucoquinasa - Google Patents
Pirazoles como activadores de glucoquinasaInfo
- Publication number
- AR062012A1 AR062012A1 ARP070103249A ARP070103249A AR062012A1 AR 062012 A1 AR062012 A1 AR 062012A1 AR P070103249 A ARP070103249 A AR P070103249A AR P070103249 A ARP070103249 A AR P070103249A AR 062012 A1 AR062012 A1 AR 062012A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- lower alkyl
- hydrogen
- alkyl
- hydroxy
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 18
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 12
- -1 amino, hydroxyamino Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 2
- 229920001774 Perfluoroether Chemical group 0.000 abstract 2
- 229910006080 SO2X Inorganic materials 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229930192474 thiophene Natural products 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 abstract 1
- WPWNEKFMGCWNPR-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene Chemical compound C1=CC=C2CCCSC2=C1 WPWNEKFMGCWNPR-UHFFFAOYSA-N 0.000 abstract 1
- CJZFOZAQGBLEFL-UHFFFAOYSA-N 3,4-dihydro-2h-thiochromene 1-oxide Chemical compound C1=CC=C2S(=O)CCCC2=C1 CJZFOZAQGBLEFL-UHFFFAOYSA-N 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Útiles para el tratamiento de enfermedades y trastornos metabólicos, con preferencia la diabetes mellitus. Reivindicación 1: Un compuesto de la fórmula (1) en la que R¹ y R² se eligen con independencia entre el grupo formado por hidrógeno, halógeno, amino, hidroxiamino, ciano, nitro, alquilo inferior, -OR⁵, -C(O)OR⁶, perfluoro-alquilo inferior, alquiltio inferior, perfluoro-alquiltio inferior, alquilsulfinilo inferior, alquilsulfonilo inferior, cicloalquil-alquilsulfonilo inferior, (alcoxi inferior)-alquilsulfonilo inferior, perfluoro-alquilsulfonilo inferior y sulfonamido; o R¹ y R², junto con el anillo fenilo, al que están unidos, se combinan para formar un grupo elegido entre el grupo formado por 2,3-dihidro-benzo[b]tiofeno, 1-óxido de 2,3-dihidro-benzo[b]tiofeno, 1,1-dióxido de 2,3-dihidro-benzo[b]tiofeno, benzo[b]tiofeno, 1-óxido de benzo[b]tiofeno, 1,1-dióxido de benzo[b]tiofeno, tiocromano, 1-óxido de tiocromano y 1,1-dióxido de tiocromano; R³ es un cicloalquilo, un bicicloalquilo o un heterociclo mono- o bicíclico de 1-3 heteroátomos, elegido entre N, O y S, dicho cicloalquilo o heterociclo está sin sustituir o mono-, bi- o trisustituido con grupos elegidos entre el grupo formado por halógeno, alquilo inferior, alcoxi inferior, carbonilo y alquilsulfonilo inferior; R⁴ se elige entre el grupo formado por hidrógeno, los compuestos del grupo de fórmulas (2), alquilo C₁₋₁₀ y alquenilo C₂₋₁₀; R⁵ se elige entre el grupo formado por hidrógeno, alquilo C₁₋₆, fenilo, bencilo, fenilo sustituido y bencilo sustituido; R⁶ se elige entre el grupo formado por hidrógeno, alquilo C₁₋₆, bencilo y bencilo sustituido; R⁷ se elige entre el grupo formado por hidrógeno, hidroxi, alcoxi, perfluoro-alcoxi, amino, alquilamino, dialquilamino, hidroximetilo, C(O)OY', en el que Y' es H o alquilo inferior y -O-C(O)-CH₃; R⁸ es hidrógeno o alquilo inferior; R⁹ se elige entre el grupo formado por hidrógeno, cicloalquilo y alquilo inferior; R¹⁰ se elige entre el grupo formado por hidroxi, alcoxi inferior, amino, metilamino, dimetilamino o -NH-CH₂-cicloalquilo; R¹¹ se elige entre el grupo formado por hidroxi, amino, alquilamino inferior, ciclopropil-metil-amino, metoxi y NHCH₂CH₂CH₂L, en el que L es metoxi, hidroxi o dimetilamino; R¹² es hidrógeno o alquilo inferior; R¹³ es hidrógeno o alquilo inferior; R¹⁴ se elige entre el grupo formado por hidrógeno, alquilo inferior, SO₂X, en el que X es alquilo inferior, y C(O)Y, en el que Y es alquilo inferior u O-alquilo; R¹⁵ se elige entre el grupo formado por hidroxi, metoxi, t-butoxi, alquilo inferior, 2-hidroxi-2-metil-propilo, amino, metilamino, propilamino, dimetilamino, dietilamino, morfolino, fenilamino, bencilamino, alilcarbamoil-alquilo inferior, alilamino, pirazin-2-ilamino y NH-(CH₂)ᵛZ, en el que Z es metoxi o morfolino; R¹⁶ es alquilo inferior; R¹⁷ es metoxi; R¹⁸ se elige entre el grupo formado por hidrógeno, alquilo inferior y C(O)R', en el que R' es alquilo inferior; X e Y se eligen con independencia entre el grupo formado por hidrógeno, halógeno, ciano, alquilo inferior, metoxi, SO₂X, en el que X es alquilo y cicloalquilo; m es el número 0, 1, 2, 3 ó 4; en el que, si m es 0, R⁷ no puede ser hidroxi, alcoxi, perfluoro-alcoxi, amino, alquilamino ni dialquilamino; n es el número 0, 1 ó 2; p es el número 0 ó 1; q es el número 0, 1 ó 2; y v es el número 2 ó 3; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83290706P | 2006-07-24 | 2006-07-24 | |
| US93081907P | 2007-05-18 | 2007-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062012A1 true AR062012A1 (es) | 2008-08-10 |
Family
ID=38657003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103249A AR062012A1 (es) | 2006-07-24 | 2007-07-20 | Pirazoles como activadores de glucoquinasa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7935699B2 (es) |
| EP (2) | EP2046755A2 (es) |
| JP (1) | JP2009544648A (es) |
| KR (1) | KR20090025358A (es) |
| AR (1) | AR062012A1 (es) |
| AU (1) | AU2007278261A1 (es) |
| BR (1) | BRPI0715531A2 (es) |
| CA (1) | CA2657566A1 (es) |
| CL (1) | CL2007002121A1 (es) |
| IL (1) | IL196321A0 (es) |
| MX (1) | MX2009000688A (es) |
| NO (1) | NO20090064L (es) |
| PE (1) | PE20080406A1 (es) |
| RU (1) | RU2009105818A (es) |
| TW (1) | TWI332948B (es) |
| WO (1) | WO2008012227A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP5248477B2 (ja) | 2007-03-07 | 2013-07-31 | 杏林製薬株式会社 | グルコキナーゼ活性化物質 |
| KR20100113518A (ko) * | 2008-01-18 | 2010-10-21 | 아스텔라스세이야쿠 가부시키가이샤 | 페닐아세트아미드 유도체 |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| CN105315224B (zh) | 2008-04-28 | 2018-04-10 | 杏林制药株式会社 | 环戊基丙烯酰胺衍生物 |
| UA104742C2 (uk) * | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
| US20110021570A1 (en) * | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
| EP2540908B1 (en) * | 2010-02-23 | 2017-04-26 | Seiren Co., Ltd. | Moisture-permeable water-proof fabric |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| US8470866B2 (en) | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
| WO2014050084A1 (ja) * | 2012-09-26 | 2014-04-03 | 興和株式会社 | 新規なフェニルアセトアミド化合物、及びそれを含有する医薬 |
| SG11201609974PA (en) | 2014-06-03 | 2016-12-29 | Actelion Pharmaceuticals Ltd | Pyrazole compounds and their use as t-type calcium channel blockers |
| US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
| AU2017378092B2 (en) | 2016-12-16 | 2023-11-23 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a T-type calcium channel blocker |
| WO2018141961A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| CN108727309B (zh) * | 2018-06-20 | 2023-04-07 | 天津全和诚科技有限责任公司 | 一种3-氧杂环丁烷羧酸的合成方法 |
| CN108947940A (zh) * | 2018-06-20 | 2018-12-07 | 天津全和诚科技有限责任公司 | 一种2-氧杂环丁烷衍生物的合成方法 |
| CN109053496B (zh) * | 2018-08-09 | 2020-10-20 | 吉尔生化（上海）有限公司 | 一种3-Boc-氨甲基环丁酮的合成方法 |
| CN114940658A (zh) * | 2022-05-12 | 2022-08-26 | 山东华阳药业有限公司 | 一种色瑞替尼的制备工艺及其制备方法 |
| CN120136817A (zh) * | 2025-05-16 | 2025-06-13 | 安徽泽升科技股份有限公司 | 一种氧杂环丁烷-3-甲醇和氧杂环丁烷-3-甲醛的制备方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200396A3 (en) | 1999-03-29 | 2003-04-28 | Hoffmann La Roche | Gluckokinase activators, process for their preparation, pharmaceutical compositions containing them and their use |
| AU2001270494B2 (en) | 2000-05-03 | 2005-11-10 | F. Hoffmann-La Roche Ag | Alkynyl phenyl heteroaromatic glucokinase activators |
| PT1283830E (pt) | 2000-05-08 | 2008-08-18 | Hoffmann La Roche | Activadores da glucoquinase de fenilamida substituída com para-amino |
| EP1282611B1 (en) | 2000-05-08 | 2004-10-20 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| ATE316965T1 (de) | 2000-12-06 | 2006-02-15 | Hoffmann La Roche | Kondensierte heteroaromatische glucokinaseaktivatoren |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| RS93604A (sr) | 2002-04-26 | 2007-02-05 | F. Hoffmann-La Roche Ag., | Supstituisani fenilacetamidi i njihova primena kao aktivatori glukokinaze |
| JP2006509774A (ja) | 2002-10-03 | 2006-03-23 | ノバルティス アクチエンゲゼルシャフト | ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| EP1594863A1 (en) | 2003-02-11 | 2005-11-16 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| AR045414A1 (es) * | 2003-02-13 | 2005-10-26 | Banyu Pharma Co Ltd | Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen. |
| NZ541824A (en) * | 2003-02-26 | 2010-04-30 | Banyu Pharma Co Ltd | Heteroarylcarbamoylbenzene derivatives as glucokinase activators |
| US20080312207A1 (en) | 2004-02-18 | 2008-12-18 | Craig Johnstone | Compounds |
| RU2392275C2 (ru) | 2004-02-18 | 2010-06-20 | Астразенека Аб | Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов |
| US7687502B2 (en) | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
| BRPI0509573A (pt) | 2004-04-02 | 2007-09-25 | Novartis Ag | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 |
| BRPI0509543A (pt) | 2004-04-02 | 2007-09-18 | Novartis Ag | derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase |
| AU2005235798A1 (en) | 2004-04-21 | 2005-11-03 | Prosidion Limited | Tri(cyclo) substituted amide compounds |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
| WO2006016194A1 (en) * | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| US8148412B2 (en) | 2004-12-03 | 2012-04-03 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| EP1910350A1 (en) | 2005-07-09 | 2008-04-16 | AstraZeneca AB | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
| JP4651714B2 (ja) | 2005-07-09 | 2011-03-16 | アストラゼネカ アクチボラグ | 糖尿病の治療においてｇｌｋ活性化剤として使用するためのヘテロアリールベンズアミド誘導体 |
| EP2027113A1 (en) | 2005-07-09 | 2009-02-25 | AstraZeneca AB | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| CA2613303C (en) | 2005-07-11 | 2012-06-19 | Mitsubishi Tanabe Pharma Corporation | An oxime derivative for use as a glucokinase activator |
| WO2007017649A1 (en) | 2005-08-09 | 2007-02-15 | Astrazeneca Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
| RU2008112184A (ru) | 2005-08-31 | 2009-10-10 | Астеллас Фарма Инк. (Jp) | Производное тиазола |
| GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| AU2006310475A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd | Tricyclo substituted amides |
| US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
-
2007
- 2007-07-16 KR KR1020097001515A patent/KR20090025358A/ko not_active Ceased
- 2007-07-16 CA CA002657566A patent/CA2657566A1/en not_active Abandoned
- 2007-07-16 EP EP07787582A patent/EP2046755A2/en not_active Withdrawn
- 2007-07-16 WO PCT/EP2007/057315 patent/WO2008012227A2/en not_active Ceased
- 2007-07-16 RU RU2009105818/04A patent/RU2009105818A/ru not_active Application Discontinuation
- 2007-07-16 MX MX2009000688A patent/MX2009000688A/es not_active Application Discontinuation
- 2007-07-16 EP EP10175986A patent/EP2261216A3/en not_active Withdrawn
- 2007-07-16 JP JP2009521210A patent/JP2009544648A/ja active Pending
- 2007-07-16 AU AU2007278261A patent/AU2007278261A1/en not_active Abandoned
- 2007-07-16 BR BRPI0715531-0A2A patent/BRPI0715531A2/pt not_active IP Right Cessation
- 2007-07-19 US US11/879,935 patent/US7935699B2/en not_active Expired - Fee Related
- 2007-07-20 TW TW096126648A patent/TWI332948B/zh not_active IP Right Cessation
- 2007-07-20 CL CL200702121A patent/CL2007002121A1/es unknown
- 2007-07-20 AR ARP070103249A patent/AR062012A1/es not_active Application Discontinuation
- 2007-07-23 PE PE2007000954A patent/PE20080406A1/es not_active Application Discontinuation
-
2009
- 2009-01-01 IL IL196321A patent/IL196321A0/en unknown
- 2009-01-06 NO NO20090064A patent/NO20090064L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200812974A (en) | 2008-03-16 |
| JP2009544648A (ja) | 2009-12-17 |
| AU2007278261A1 (en) | 2008-01-31 |
| RU2009105818A (ru) | 2010-08-27 |
| EP2046755A2 (en) | 2009-04-15 |
| EP2261216A3 (en) | 2011-12-14 |
| NO20090064L (no) | 2009-02-04 |
| KR20090025358A (ko) | 2009-03-10 |
| TWI332948B (en) | 2010-11-11 |
| CA2657566A1 (en) | 2008-01-31 |
| EP2261216A2 (en) | 2010-12-15 |
| US7935699B2 (en) | 2011-05-03 |
| WO2008012227A3 (en) | 2008-05-15 |
| WO2008012227A2 (en) | 2008-01-31 |
| BRPI0715531A2 (pt) | 2014-06-24 |
| IL196321A0 (en) | 2009-09-22 |
| US20080021032A1 (en) | 2008-01-24 |
| MX2009000688A (es) | 2009-01-30 |
| WO2008012227A8 (en) | 2008-09-12 |
| CL2007002121A1 (es) | 2008-02-22 |
| PE20080406A1 (es) | 2008-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062012A1 (es) | Pirazoles como activadores de glucoquinasa | |
| AR063081A1 (es) | Derivados de 3- aza- biciclo [3.1.0] hexano y su uso para la preparacion de medicamentos | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| ES2580803T3 (es) | Moduladores de transportadores del casete de unión a ATP | |
| AR122776A2 (es) | Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR á7 | |
| AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
| AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| PE20191817A1 (es) | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
| AR033686A1 (es) | Nuevos derivados de n-(arilsulfonil)beta-aminoacidos que comprenden un grupo aminometilo substituido, su preparacion, y las composiciones farmaceuticas que los contienen | |
| AR054280A1 (es) | Derivados de carboxamidas y su empleo en procedimientos de lucha contra enfermedades de plantas y contra hongos nocivos | |
| AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
| AR068547A1 (es) | Derivados de quinolina | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
| AR065822A1 (es) | Derivados de tiazolidina. composiciones farmaceuticas y usos como antagonistas del receptor orexina | |
| AR058919A1 (es) | Compuestos de heteroarilo biciclicos como inhibidores de pde10, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del snc. | |
| AR083635A1 (es) | Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales | |
| AR063898A1 (es) | Derivados de dihidro-h-pirazolo[4,3c]piridazin-3-ona sustituidos,metodo de preparacion,composiciones farmaceuticas que los contienen u usos en terapeutica para prevenir o tratar enfermedades en las que estan implicados receptores canabinoides cb1. | |
| AR049521A1 (es) | Derivados de pirrazol - pirimidina | |
| AR107249A1 (es) | Compuestos depsipeptídicos como anthelmínticos | |
| AR105544A1 (es) | Compuestos de n-carboxamida cíclica útiles como herbicidas | |
| ES2271537T3 (es) | Derivados de benzofurano y benzotiofeno utiles en el tratamiento de trastornos hiperproliferativos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |